Twist Bioscience lands Eli Lilly TuneLab deal, stock up 7.02%

Twist Bioscience occupies a differentiated position in synthetic biology and NGS tools, with 52% gross margin and nearly 10% three-year and 28% five-year revenue CAGRs. However, the company remains loss-making and capital consumptive, with an EBIT margin of -31.8% and free cash flow of -$8.6M in the latest quarter. The stock trades at a demanding valuation of around 22x sales, embedding high execution expectations.

The Lilly TuneLab collaboration and visible AI-driven antibody discovery demand, plus Leerink's $160 target and UBS's $144 initiation, position Twist at the high-growth end of tools versus peers that grow mid-single to low-double digits. The stock has moved from $134 to $168 in four sessions, with consecutive higher highs and strong closes near the top of the intraday range, confirming aggressive dip-buying and high volume following the Lilly AI news.

Looking ahead, the risk/reward appears favorable but volatile. The outcome hinges on whether the AI-driven opportunity converts into revenue and whether the company can manage its cash burn. For investors, the key will be monitoring the translation of the Lilly collaboration into orders and the sustainability of the current momentum above the $150 support level.